吉西他滨联合多西他赛化疗引起尿失禁,临床案例报告

发布时间：2018-05-29 01:06

本文选题：吉西他滨 + 多西他赛　；参考：《基因组学与应用生物学》2017年03期

【摘要】：本研究报告了吉西他滨联合多西他赛化疗引起尿失禁的一例临床案例。我们运用Naranjo's评估量表分析了吉西他滨联合多西他赛化疗与尿失禁不良反应之间的相关性及紧密程度。分析了关于吉西他滨联合多西他赛化疗药品不良反应,阐述了吉西他滨联合多西他赛化疗引起尿失禁的可能机制。根据Naranjo's评估量表评分总分值为7分,说明了吉西他滨联合多西他赛化疗引起尿失禁的可能性较高,但是吉西他滨联合多西他赛化疗引起尿失禁的机制尚不明确,我们推测可能与多西他赛的神经毒性有一定关系,药物神经毒性引起膀胱与尿道平滑肌功能失调,导致尿失禁。然而,尿失禁的发病机制与多种因素有关,因此在临床上尚需更多病例观察以明其机制,从而有效改善相关药物不良反应的发生,提高患者的生存质量。
[Abstract]:This study reports a case of urinary incontinence caused by gemcitabine combined with docetaxel chemotherapy. We analyzed the correlation and tightness between gemcitabine combined with docetaxel chemotherapy and adverse effects of urinary incontinence using Naranjo's scale. The adverse drug reactions of gemcitabine combined with docetaxel were analyzed and the possible mechanism of urinary incontinence induced by gemcitabine combined with docetaxel was discussed. The total score of Naranjo's evaluation scale is 7, which indicates that gemcitabine combined with docetaxel chemotherapy is more likely to cause urinary incontinence, but the mechanism of gemcitabine combined with docetaxel chemotherapy induced urinary incontinence is not clear. We speculate that it may be related to the neurotoxicity of docetaxel, which results in bladder and urethral smooth muscle dysfunction and urinary incontinence. However, the pathogenesis of urinary incontinence is related to many factors, so it is necessary to observe more cases in clinic in order to improve the occurrence of adverse drug reactions and improve the quality of life of patients.
【作者单位】：浙江大学附属第一医院;
【基金】：国家自然科学基金项目(No.81400958)资助
【分类号】：R730.53

【相似文献】